Dr. Benjamin W. Friedman, MD | Bronx ...

Dr. Benjamin W Friedman, MD

Claim this profile

Montefiore Medical Center

Studies Unexplained Vomiting
Studies Nausea and Vomiting
9 reported clinical trials
10 drugs studied

Affiliated Hospitals

Image of trial facility.
Montefiore Medical Center
Image of trial facility.
Montefiore

Clinical Trials Benjamin W Friedman, MD is currently running

Image of trial facility.

Central Venous Catheter Techniques

for Shock

Two different techniques for placing a central venous catheter will be compared. The studyu team hypothesizes that clinicians randomized to the peripheral catheter technique will have higher first attempt success rates, fewer procedural complications, and a shorter mean time to procedure completion than physicians assigned to wire through hollow bore needle.
Recruiting3 awards Phase 4
Image of trial facility.

Fosaprepitant

for Nausea and Vomiting

The study team proposes a randomized, double-blind, RCT to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic ondansetron. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in EDs. Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time. The outcome for the efficacy analysis will be no need for additional medication to treat nausea and vomiting within 2 hours of investigational medication administration. The primary outcome for the tolerability analysis will be the development of any new symptom within 2 hours of medication administration.
Recruiting1 award Phase 2 & 3

More about Benjamin W Friedman, MD

Clinical Trial Related4 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Benjamin W Friedman, MD has experience with
  • Fosaprepitant
  • Dexamethasone
  • Central Venous Catheter Insertion
  • Metoclopramide
  • Oxycodone
  • Acetaminophen

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Benjamin W Friedman, MD specialize in?
Is Benjamin W Friedman, MD currently recruiting for clinical trials?
Are there any treatments that Benjamin W Friedman, MD has studied deeply?
What is the best way to schedule an appointment with Benjamin W Friedman, MD?
What is the office address of Benjamin W Friedman, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security